Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
FDA official and rare‑disease patient recounts liver transplants and family caregiving
Loading...
Summary
At a Rare Disease Week town hall, a patient‑advocate who now holds leadership at the FDA shared a multi‑decade transplant journey, the role of living donors in his family's survival and how personal experience shaped his advocacy for data‑driven care.
At an FDA virtual town hall, Speaker 2 recounted a decades‑long experience with primary sclerosing cholangitis that led to multiple liver transplants and a family‑led effort to save his daughter. Speaker 2 described early symptoms in his twenties, a formal diagnosis, and the eventual need for transplant after disease progression.
He detailed the logistics and risks of living‑donor liver transplantation—"it's a 10 to 12 hour surgery for both the donor and the recipient," he said—and explained that surgeons remove roughly two‑thirds of a donor's liver, which then regenerates. He described experimental therapy use in his first transplant and a period of septic shock between procedures.
Speaker 2 also highlighted caregiver burdens, saying many families "put their life on hold" and citing speaker estimates of tens of millions of Americans who serve as caregivers and millions living with rare diseases. He described the emotional arc of rare‑disease care as moving "from fear to hope," quoting his daughter's remark after recovery: "I could dream again."
The patient said his personal experience shaped a professional pivot: he used analytic tools from his earlier technical career to trend bloodwork and design an algorithm to predict rejection episodes, which he credits with helping him and informing post‑transplant care. That experience led him to explore creating a health‑care company in partnership with academic medical centers.
Speakers emphasized caregiver roles and the importance of engaging parents and patient advocates in regulatory discussions. The town hall closed with calls for continued dialogue between the FDA, clinicians and patient communities.
